Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.

Adam K, Lambert M, Lestang E, Champenois G, Dusanter-Fourt I, Tamburini J, Bouscary D, Lacombe C, Zermati Y, Mayeux P.

Biosci Rep. 2015 Oct 23;35(6). pii: e00274. doi: 10.1042/BSR20150217.

2.

Viability and stress protection of chronic lymphoid leukemia cells involves overactivation of mitochondrial phosphoSTAT3Ser727.

Capron C, Jondeau K, Casetti L, Jalbert V, Costa C, Verhoeyen E, Massé JM, Coppo P, Béné MC, Bourdoncle P, Cramer-Bordé E, Dusanter-Fourt I.

Cell Death Dis. 2014 Oct 9;5:e1451. doi: 10.1038/cddis.2014.393. Erratum in: Cell Death Dis. 2015;6:e1627. Verhoyen, E [corrected to Verhoeyen, E].

3.

CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.

4.

A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB.

Souissi I, Najjar I, Ah-Koon L, Schischmanoff PO, Lesage D, Le Coquil S, Roger C, Dusanter-Fourt I, Varin-Blank N, Cao A, Metelev V, Baran-Marszak F, Fagard R.

BMC Cell Biol. 2011 Apr 12;12:14. doi: 10.1186/1471-2121-12-14.

5.

IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis.

Malamut G, El Machhour R, Montcuquet N, Martin-Lannerée S, Dusanter-Fourt I, Verkarre V, Mention JJ, Rahmi G, Kiyono H, Butz EA, Brousse N, Cellier C, Cerf-Bensussan N, Meresse B.

J Clin Invest. 2010 Jun;120(6):2131-43. doi: 10.1172/JCI41344. Epub 2010 May 3.

6.

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.

Harir N, Boudot C, Friedbichler K, Sonneck K, Kondo R, Martin-Lannerée S, Kenner L, Kerenyi M, Yahiaoui S, Gouilleux-Gruart V, Gondry J, Bénit L, Dusanter-Fourt I, Lassoued K, Valent P, Moriggl R, Gouilleux F.

Blood. 2008 Sep 15;112(6):2463-73. doi: 10.1182/blood-2007-09-115477. Epub 2008 Jun 25. Erratum in: Blood. 2009 Aug 20;114(8):1720.

7.

Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPARgamma/STAT5 signaling pathway in macaques.

Prost S, Le Dantec M, Augé S, Le Grand R, Derdouch S, Auregan G, Déglon N, Relouzat F, Aubertin AM, Maillere B, Dusanter-Fourt I, Kirszenbaum M.

J Clin Invest. 2008 May;118(5):1765-75. doi: 10.1172/JCI33037.

8.
9.

STAT5 and Oct-1 form a stable complex that modulates cyclin D1 expression.

Magné S, Caron S, Charon M, Rouyez MC, Dusanter-Fourt I.

Mol Cell Biol. 2003 Dec;23(24):8934-45.

10.

Spi-1/PU.1 is a positive regulator of the Fli-1 gene involved in inhibition of erythroid differentiation in friend erythroleukemic cell lines.

Starck J, Doubeikovski A, Sarrazin S, Gonnet C, Rao G, Skoultchi A, Godet J, Dusanter-Fourt I, Morle F.

Mol Cell Biol. 1999 Jan;19(1):121-35.

11.

Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway.

Rouyez MC, Boucheron C, Gisselbrecht S, Dusanter-Fourt I, Porteu F.

Mol Cell Biol. 1997 Sep;17(9):4991-5000.

12.

A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein.

Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, Levin J, Bernard O, Ghysdael J.

EMBO J. 1997 Jan 2;16(1):69-82.

13.

Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation.

Gobert S, Chretien S, Gouilleux F, Muller O, Pallard C, Dusanter-Fourt I, Groner B, Lacombe C, Gisselbrecht S, Mayeux P.

EMBO J. 1996 May 15;15(10):2434-41.

14.

Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin.

Porteu F, Rouyez MC, Cocault L, Bénit L, Charon M, Picard F, Gisselbrecht S, Souyri M, Dusanter-Fourt I.

Mol Cell Biol. 1996 May;16(5):2473-82.

15.

Thrombopoietin activates a STAT5-like factor in hematopoietic cells.

Pallard C, Gouilleux F, Bénit L, Cocault L, Souyri M, Levy D, Groner B, Gisselbrecht S, Dusanter-Fourt I.

EMBO J. 1995 Jun 15;14(12):2847-56.

16.

Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity.

Gouilleux F, Pallard C, Dusanter-Fourt I, Wakao H, Haldosen LA, Norstedt G, Levy D, Groner B.

EMBO J. 1995 May 1;14(9):2005-13.

17.

Characterization of mpl cytoplasmic domain sequences required for myeloproliferative leukemia virus pathogenicity.

Bénit L, Courtois G, Charon M, Varlet P, Dusanter-Fourt I, Gisselbrecht S.

J Virol. 1994 Aug;68(8):5270-4.

18.

Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin-erythropoietin receptor chimera expressed in lymphoid cells.

Dusanter-Fourt I, Muller O, Ziemiecki A, Mayeux P, Drucker B, Djiane J, Wilks A, Harpur AG, Fischer S, Gisselbrecht S.

EMBO J. 1994 Jun 1;13(11):2583-91.

19.

Identification and sequence analysis of a second form of prolactin receptor by molecular cloning of complementary DNA from rabbit mammary gland.

Edery M, Jolicoeur C, Levi-Meyrueis C, Dusanter-Fourt I, Pétridou B, Boutin JM, Lesueur L, Kelly PA, Djiane J.

Proc Natl Acad Sci U S A. 1989 Mar;86(6):2112-6.

Supplemental Content

Loading ...
Support Center